Brett Monia, Ionis Pharmaceuticals CEO

Io­n­is plans NDA fil­ing for first in­de­pen­dent drug af­ter pos­i­tive da­ta read­out in rare ge­net­ic dis­or­der

Io­n­is is an­oth­er step clos­er to the launch of its first in­de­pen­dent drug, tout­ing pos­i­tive Phase III da­ta for olezarsen in pa­tients with a rare …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.